Condition: Glioblastoma Multiforme · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.
This description comes directly from the study's public registry record.
Lawrence Kleinberg, MD · 410-614-2597 · kleinla@jhmi.edu
Ipshita Faldu · 667-306-8336 · ifaldu1@jhu.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Medical Institution | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05083754